Mark Albertini, MD

Hematology, Medical Oncology and Palliative Care
Clinical Science Center
600 Highland Ave K6/530
Madison WI 53792-0001
(608) 263-0117


  • University of Vermont, College of Medicine, Burlington, VT – MD
  • University of Wisconsin Hospital and Clinics – Residency in Internal Medicine
  • University of Wisconsin–Madison – Postdoctoral Fellowship in Tumor Immunology
  • University of Wisconsin Carbone Cancer Center – Fellowships in Medical Oncology and Biotherapy

Professional Activities

Dr. Mark Albertini is a faculty member in the Division of Hematology, Medical Oncology and Palliative Care within the Department of Medicine. He is the founder of the UW Carbone Cancer Center Comprehensive Melanoma Clinic, the director of the UW Carbone Cancer Center Melanoma Disease-Oriented working group and the Chief of Oncology at the William S. Middleton Memorial Veterans Hospital. Dr. Albertini has received a Professionalism Award from Department of Medicine housestaff, has received a UW Health Patient Experience Physician Champion Award, and has been selected for listing by the Best Doctors in America organization. He serves on several regional and national scientific review panels and is a reviewer for 15 scientific journals.

Clinical Specialties

Dr. Albertini is a medical oncologist with special interests in the treatment and monitoring of malignant melanoma.

Research Interests

View Dr. Mark Albertini's publications on NCBI My Bibliography

Dr. Albertini is nationally known melanoma researcher. The overall goal of his translational melanoma research program is to provide an understanding of the immunobiology of human malignant melanoma as a means to develop an effective immunotherapy for patients with this disease. This goal is pursued with clinical and laboratory studies involving patients receiving novel immunotherapies and with a preclinical spontaneous canine melanoma model to direct subsequent human studies. He has been protocol chairman for melanoma studies investigating chemotherapy, cytokines, monoclonal antibodies, immunocytokines, and DNA vaccines. He directs a laboratory research program that is investigating novel immune monitoring of melanoma patients as well as immunocytokines as a potential treatment to bring to the clinic.